Advertisement

Ads Placeholder
Loading...

HUTCHMED (China) Limited

0013.HKHKSE
Healthcare
Drug Manufacturers - Specialty & Generic
HK$23.56
HK$-0.32(-1.34%)
Hong Kong Market opens in 4h 55m

HUTCHMED (China) Limited Fundamental Analysis

HUTCHMED (China) Limited (0013.HK) shows moderate financial fundamentals with a PE ratio of 5.71, profit margin of 1.05%, and ROE of 41.38%. The company generates $0.4B in annual revenue with weak year-over-year growth of -24.80%.

Key Strengths

ROE41.38%
PEG Ratio0.54
Current Ratio4.96

Areas of Concern

Operating Margin-2.64%
We analyze 0013.HK's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 39.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
39.3/100

We analyze 0013.HK's fundamental strength across five key dimensions:

Efficiency Score

Excellent

0013.HK demonstrates superior asset utilization.

ROA > 10%
26.29%

Valuation Score

Excellent

0013.HK trades at attractive valuation levels.

PE < 25
5.71
PEG Ratio < 2
0.54

Growth Score

Weak

0013.HK faces weak or negative growth trends.

Revenue Growth > 5%
-24.80%
EPS Growth > 10%
-63.42%

Financial Health Score

Excellent

0013.HK maintains a strong and stable balance sheet.

Debt/Equity < 1
0.08
Current Ratio > 1
4.96

Profitability Score

Weak

0013.HK struggles to sustain strong margins.

ROE > 15%
41.38%
Net Margin ≥ 15%
1.05%
Positive Free Cash Flow
No

Key Financial Metrics

Is 0013.HK Expensive or Cheap?

P/E Ratio

0013.HK trades at 5.71 times earnings. This suggests potential undervaluation.

5.71

PEG Ratio

When adjusting for growth, 0013.HK's PEG of 0.54 indicates potential undervaluation.

0.54

Price to Book

The market values HUTCHMED (China) Limited at 2.12 times its book value. This may indicate undervaluation.

2.12

EV/EBITDA

Enterprise value stands at -1046.52 times EBITDA. This is generally considered low.

-1046.52

How Well Does 0013.HK Make Money?

Net Profit Margin

For every $100 in sales, HUTCHMED (China) Limited keeps $1.05 as profit after all expenses.

1.05%

Operating Margin

Core operations generate -2.64 in profit for every $100 in revenue, before interest and taxes.

-2.64%

ROE

Management delivers $41.38 in profit for every $100 of shareholder equity.

41.38%

ROA

HUTCHMED (China) Limited generates $26.29 in profit for every $100 in assets, demonstrating efficient asset deployment.

26.29%

Following the Money - Real Cash Generation

Operating Cash Flow

HUTCHMED (China) Limited generates limited operating cash flow of $-51.80M, signaling weaker underlying cash strength.

$-51.80M

Free Cash Flow

HUTCHMED (China) Limited generates weak or negative free cash flow of $-64.75M, restricting financial flexibility.

$-64.75M

FCF Per Share

Each share generates $-0.08 in free cash annually.

$-0.08

FCF Yield

0013.HK converts -2.55% of its market value into free cash.

-2.55%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

5.71

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.54

vs 25 benchmark

P/B Ratio

Price to book value ratio

2.12

vs 25 benchmark

P/S Ratio

Price to sales ratio

5.87

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.08

vs 25 benchmark

Current Ratio

Current assets to current liabilities

4.96

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.41

vs 25 benchmark

ROA

Return on assets percentage

0.26

vs 25 benchmark

ROCE

Return on capital employed

-0.01

vs 25 benchmark

How 0013.HK Stacks Against Its Sector Peers

Metric0013.HK ValueSector AveragePerformance
P/E Ratio5.7128.45 Better (Cheaper)
ROE41.38%763.00% Weak
Net Margin104.77%-45265.00% (disorted) Strong
Debt/Equity0.080.34 Strong (Low Leverage)
Current Ratio4.962795.60 Strong Liquidity
ROA26.29%-16588.00% (disorted) Strong

0013.HK outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews HUTCHMED (China) Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

138.07%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

120.23%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

100.48%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ